(Q36034728)

11 August 2017

1 reference

title

From heparins to factor Xa inhibitors and beyond (English)

1 reference

11 August 2017

Alban S

1

1 reference

11 August 2017

1 March 2005

1 reference

European Journal of Clinical Investigation

11 August 2017

1 reference

11 August 2017

35 Suppl 1

1 reference

11 August 2017

12-20

1 reference

11 August 2017

The chemistry of heparin

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Direct thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Low-molecular-weight heparins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Synthesis of thrombin-inhibiting heparin mimetics without side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

New synthetic heparin mimetics able to inhibit thrombin and factor Xa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0960-135X.2005.01452.X

10.1111/J.0960-135X.2005.01452.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15701143